Objective: To investigate whether the magnitude of presynaptic dopamine depletion is a risk factor for the development of levodopa-induced dyskinesia (LID) in Parkinson disease (PD) by quantitatively analyzing 18 F-FP-CIT PET data.
Levodopa-induced dyskinesia (LID) is one of the most disabling complications in patients with Parkinson disease (PD) who are treated chronically with levodopa. Observational studies have reported that about 60% of patients with PD treated with levodopa for 5 years had experienced LID, 1, 2 and randomized clinical trials have also shown that LID developed in approximately half of patients with PD after 4 years of levodopa treatment. [3] [4] [5] In terms of risk factors, the development of LID is closely associated with higher dose of levodopa, 1, 6 longer duration of levodopa treatment, 7 and younger age at onset of PD. 2, 8 In addition, lower body weight, 9 female sex, 10 and genetic susceptibility 11 have also been suggested as contributors to increase risk for LID. Although the mechanism for LID is not completely understood, presynaptic dopaminergic denervation has been considered essential for its development, along with chronic pulsatile stimulation of dopamine receptors. 12 Of importance, animal studies have indicated that nigrostriatal damage is a prerequisite for LID induction and that the magnitude of nigrostriatal dopaminergic denervation is closely associated with the development of LID. [13] [14] [15] However, recent clinical studies have failed to show association between the severity of motor symptoms and development of LID. 1, 2, 7, 16 The results of functional neuroimaging analyses have also been inconsistent; some cross-sectional studies using PET reported that the degree of synaptic dopaminergic denervation was associated with motor fluctuation in patients with PD, [17] [18] [19] but these studies had small sample sizes 17, 19 or showed significant differences in terms of disease duration at baseline or age at onset. 18 Furthermore, one study observed similar degrees of presynaptic dopaminergic denervation in patients with and without LID. 20 Therefore, the present study evaluated the association between presynaptic dopaminergic depletion and LID by quantitatively analyzing 18 F-FP-CIT PET data to determine whether the magnitude of dopamine depletion may act as a risk factor for the development of LID in de novo patients with PD. METHODS Participants. This retrospective cohort study enrolled 132 patients with PD recruited from a university hospital. The participants were drug-naive de novo patients with PD who completed an 18 F-FP-CIT PET scan at the time of PD diagnosis, which was performed according to the clinical criteria of the UK PD Brain Bank. 21 The inclusion criteria were decreased dopamine transporter (DAT) uptake in the putamen and a minimum follow-up period of 2 years since beginning dopaminergic medication. Patients who had focal lesions or lacunar infarction in the basal ganglia according to MRI were excluded from the study. All patients had visited our outpatient clinic every 3-6 months, and 2 movement disorders experts (Y.H.S., P.H.L.) assessed the presence of LID based on history or direct neurologic examination at every visit. During follow-up, 2 patients were diagnosed with dementia with Lewy bodies and multiple system atrophy, and 2 experienced intracranial hemorrhage in the basal ganglia within 2 years of follow-up. Another patient was uncooperative and took medication arbitrarily. After excluding these 5 patients, we analyzed the demographic and imaging data from 127 participants for the present study. Levodopa dose was defined as the dose taken at the time of development of LID in patients with LID or at the time of last visit in those without LID. Motor symptoms were assessed using the Unified Parkinson's Disease Rating Scale (UPDRS) motor score (part III) at the time of PD diagnosis or within 6 months after initial diagnosis of PD (during the off status).
Standard protocol approvals, registrations, and patient consents. We received approval from the Yonsei University Severance Hospital ethical standards committee on human experimentation for experiments using human participants. 18 F-FP-CIT PET. 18 F-FP-CIT PET scans were performed with a GE PET-CT DSTe scanner (GE Discovery STE, GE Healthcare Technologies, Milwaukee, WI), which obtains images with 3D resolution of 2.3 mm full width at halfmaximum. All participants fasted for at least 6 hours before PET scanning. After fasting, 5 mCi (185 MBq) of 18 F-FP-CIT was injected IV, and images were acquired in a 3D mode at 120 KVp and 380 mAs during a 20-minute session that occurred 90 minutes following injection.
Quantitative analysis of 18 F-FP-CIT PET data. Quantitative analyses were performed following a modified version of a previously described procedure. 22 Image processing was performed using SPM2 (Wellcome Department of Imaging Neuroscience, Institute of Neurology, UCL, London, UK) under Matlab 6.5.1 for Windows (MathWorks, Natick, MA) and MRIcro version 1.37 (Chris Rorden, Columbia, SC). Quantitative analyses were based on volumes of interest (VOIs), which were defined based on a template in standard space. All reconstructed PET images were spatially normalized to Talairach space using a standard 18 F-FP-CIT PET template, which was made using 18 F-FP-CIT PET and T1 MRI of 13 normal controls to remove intersubject anatomical variability. Eight VOIs of bilateral striatal subregions and 1 occipital VOI were drawn on a coregistered spatially normalized single T1 MRI and 18 F-FP-CIT PET template image. The striatum was divided into the caudate, ventral striatum, anterior putamen, and posterior putamen. The VOI for the ventral striatum was defined according to previously defined criteria, 23 and the boundary between the anterior and posterior putamen was the anterior commissure coronal plane. The outer boundaries of striatal subregions were visually determined by the characteristic dense gray signal of the striatum, which readily distinguished these subregions from adjacent structures. Nine VOIs were tested against each subject's spatially normalized 18 F-FP-CIT PET image and adjusted when necessary. DAT activity was calculated by nondisplaceable binding potential, which was defined as (mean standardized uptake value of the striatal subregions VOI 2 mean standardized uptake value of the occipital VOI)/mean standardized uptake value of the occipital VOI. 24 Statistical analyses. We first compared the demographic and PET data of patients with and without LID. x 2 Tests were used for categorical variables, and independent t tests and Mann-Whitney U tests were used for continuous variables. Cox proportional hazard models were then conducted to identify the factors predictive of LID. Demographic factors with a significance level lower than 0.1 and use of antiparkinsonian drugs were included in Cox proportional hazard models; on this basis, age at onset of PD, sex, levodopa dose, use of dopamine agonists, use of monoamine oxidase B (MAO-B) inhibitors, use of catechol-O-methyl transferase (COMT) inhibitor, and body weight as well as the DAT activity of each striatal subregion were included the analyses as independent variables. Next, DAT activities according to 18 F-FP-CIT uptake were divided into tertiles based on their distributions. We evaluated the association between degree of DAT reduction and LID development using Cox proportional hazard models and log-rank tests. The subgroup with the highest DAT activity was designated as the reference.
RESULTS Demographic characteristics. The demographic characteristics of the participants are presented in table 1. The mean age at onset of PD was 62.9 years, and 53 patients (41.7%) were male. Participants were diagnosed a median of 1.0 years (range 0-5.4) after onset of motor symptoms, and the mean UPDRS motor score was 22.7. During a mean follow-up period of 3.4 years (range 2.1-5.0), 35 patients with PD (27.6%) developed LID. Patients with LID were more likely than were those without LID to be female (74.3 vs 52.2%, p 5 0.028) and to have higher UPDRS motor scores (28.4 vs 19.3, p , 0.001). Patients with LID also tended to be younger at onset of motor symptoms (60.3 vs 63.9 years, p 5 0.083), weigh less (58.7 vs 62.5 kg, p 5 0.056), and be treated with higher dose of levodopa (470.7 vs 408.7 mg, p 5 0.095) compared with those without LID. In addition, patients with LID were treated with significantly higher levodopa dose per kilogram (8.3 vs 6.7 mg/kg, p 5 0.017) compared with those without LID. We found no significant differences between groups in age at diagnosis, duration of motor symptoms prior to levodopa treatment, and use of other antiparkinsonian drugs.
DAT activity in 18 F-FP-CIT PET. UPDRS motor scores were significantly correlated with DAT activity in the caudate (r 5 20.45, p , 0.0001), ventral striatum (r 5 20.36, p 5 0.003), putamen (r 5 20.53, p , 0.0001), and striatum (r 5 20.51, p , 0.0001).
Comparison of 18 F-FP-CIT uptakes in the striatal subregions between groups are shown in table 2. Patients with LID showed less DAT activity in the putamen (1.35 vs 1.55, p 5 0.040) than did those without LID, whereas DAT activity in the ventral striatum and caudate did not differ between groups. In the putamen, the difference in DAT activity between groups was greater in the posterior portion of the putamen (1.02 vs 1.21, p 5 0.029), and this difference was consistently observed in both the more (0.85 vs 1.01, p 5 0.040) and the less affected (1.19 vs 1.41, p 5 0.037) sides.
Predictive value of DAT activity for the development of LID. Multivariate Cox regression hazard models were (table 3 ). In addition, younger age at onset of PD and higher dose of levodopa were significant predictors of LID. However, sex, body weight, use of dopamine agonists, use of MAO-B inhibitor, and use of COMT inhibitor were not significantly associated with LID development. Next, patients were grouped into tertiles based on the distribution of DAT activity on the 18 F-FP-CIT PET, and the highest tertile (the group showing a mild reduction in DAT uptake) was adopted as the reference group. The Cox proportional hazard models revealed that, compared with the mild reduction group, patients having severe (HR 3.465; 95% CI 1.343-8.939; p 5 0.010) and moderate (HR 2.973; 95% CI 1.152-7.667; p 5 0.024) reductions in DAT activity in the whole putamen were at higher risk for the development of LID, whereas the risk for LID did not differ between patients with severe and those with moderate reduction in DAT activity (logrank test, p 5 0.046; figure, A). Similarly, LID risk was higher in patients with severe and moderate reductions in DAT in the anterior putamen compared with those with mild DAT reduction (log-rank test, p 5 0.049; figure, B). In the posterior putamen, severe reduction in DAT activity was a significant predictor of the development of LID relative to moderate (HR 2.421; 95% CI 1.081-5.435; p 5 0.032) or mild (HR 3.956; 95% CI 1.627-9.615; p 5 0.002) DAT reduction (log-rank test, p 5 0.008; figure, C). DISCUSSION Based on a detailed quantification of DAT activity, the present study demonstrated that patients with PD with LID exhibited lower levels of initial DAT activity in the posterior putamen than did those without LID. In addition, multivariate Cox regression hazard models showed that in addition to younger age at onset of PD and higher dose of levodopa, DAT activity in the putamen was a significant predictor of the development of LID in drug-naive de novo patients with PD. These data confirm that degree of presynaptic dopaminergic denervation plays a crucial role in the development of LID.
Although presynaptic dopamine depletion has been theoretically considered essential for the development of LID, the association between degree of presynaptic dopamine denervation and risk of LID has been difficult to demonstrate. Several longitudinal studies explored the severity of parkinsonian motor symptoms as an indirect marker of presynaptic dopamine dysfunction; however, UPDRS motor scores are not precise reflections of the status of presynaptic dopamine denervation on PET or SPECT. Previous functional neuroimaging studies showed negative correlations between UPDRS motor scores and striatal DAT activity, but the strength of these correlations was not extremely high (r 5 20.44 to 20.68). [25] [26] [27] Moreover, the UPDRS tremor 25, 26 and rigidity 25 subscores were not correlated with presynaptic DAT activity, and postural and gait disturbance was strongly correlated with cholinergic rather than with nigrostriatal dopaminergic activity. 28 For this reason, several studies used functional imaging to evaluate the role of presynaptic dopamine depletion as a significant predictor of LID, but these studies did not employ a longitudinal design and thus were limited in their ability to draw definite conclusions.
In the present study, a quantitative analysis of 18 F-FP-CIT uptake demonstrated that DAT activity in the putamen, but not in the caudate, is a significant predictor of the development of LID. In terms of putaminal subregions, DAT activity in the posterior rather than the anterior putamen seems to be closely associated with LID development. From an anatomical perspective, the posterior putamen is a sensorimotor sector, 29 and experimental studies have shown that the molecular events leading to LID in the context of presynaptic dopamine depletion are generally more pronounced in this region. 30, 31 Indeed, a previous cross-sectional study also showed that 18 F-fluorodopa uptake in the putamen, but not the caudate, was related to the development of LID. 18 Additionally, several functional neuroimaging studies demonstrated that striatal dopaminergic denervation in patients with PD was most pronounced in the putamen, especially the postero-dorsal area, 32, 33 and subregional differences in this tendency were more pronounced in the early stage of PD. 33 Therefore, development of LID seems to be associated with the subregional vulnerability to PD of the posterior putamen as well as with molecular events that induce this disease process.
As another considering point, the Cox proportional hazard models in the present study showed that the degree of DAT activity required to induce LID may differ by putaminal subregion; severe dopamine depletion, relative to mild or moderate depletion, was associated with LID in the posterior putamen, whereas moderate dopamine depletion, relative to mild dopamine depletion, was an additional predictor of LID in the anterior putamen. This result is unexpected, and it is difficult to explain the underlying pathomechanisms. According to animal studies of LID, the striatal subregions in which LIDassociated mRNAs or proteins are strongly expressed may differ slightly, implying that the threshold for LID in the striatum may differ by region. 30, 34 Moreover, an animal study evaluating kinase pathway in PD provided evidence for regional effects of the molecular signaling involved in the development of LID and suggested the possibility that the associative sector, as well as the sensorimotor area, of the putamen may contribute to the development of LID. 30 Thus, the lower threshold for LID in the anterior putamen than in the posterior putamen may explain the difference in LID-associated DAT activity in the putamen. However, additional studies are required to examine this issue. Postsynaptic changes have recently been recognized as an important consideration in understanding LID. Supersensitivity of postsynaptic dopamine receptors and the influence of neurotransmitters other than dopamine seem to be involved in the development of LID. 12 A cross-sectional PET study also showed that the characteristics of LID were related to both presynaptic and postsynaptic dopaminergic status. 19 More recently, a clinical observation study reported LID in patients with tyrosine hydroxylase deficiency, which has normal presynaptic innervation. 35 It seems that presynaptic dopaminergic denervation is not necessary for the development of LID. However, the exogenous replacement of levodopa in response to tyrosine hydroxylase deficiency can lead to super-sensitivity of postsynaptic receptors under conditions of dopamine depletion in the synaptic cleft. Therefore, presynaptic dopamine depletion, whether due to neuronal degeneration or functional impairment, remains a prerequisite for the development of LID.
The multivariate Cox proportional hazard models indicated that higher dose of levodopa and younger age at onset of PD were also significant predictors of LID. These risk factors have been reported consistently in many previous studies. 1, 2, 6, 16 In addition, female sex and body weight were significantly associated with the development of LID in independent t tests and univariate Cox regression analyses, although this association was not significant in multivariate models. Generally, female participants weigh less than male participants, and they therefore tend to receive relatively higher levodopa dose per unit of body weight. Thus, even though neither being female nor weighing less was an independent predictor of LID in the present studies, these factors may have an effect on the development of LID via their association with increased concentration of levodopa. 16 The strengths and limitations of the present study need to be addressed. The present research is the first longitudinal study using a detailed quantification of DAT activity, and it included a relatively larger number of de novo patients with PD. Nevertheless, this study is limited in its ability to draw definitive conclusions due to its retrospective design. Second, we evaluated DAT activity at baseline but could not determine changes in this activity. As the degeneration of dopaminergic neurons did not follow a linear pattern and the rate of such degeneration also varied substantially, 33, 36 further research regarding whether the rate of degeneration is predictive of development of LID is needed. Finally, this observational study did not include allocation information of different antiparkinsonian drug regimens, which may act as a confounding factor for the present results. Controversy about whether dopamine agonists are neuroprotective, whether levodopa is toxic, and whether selegiline is neuroprotective persists. 6, [37] [38] [39] Although patients with and without LID did not differ in their use of antiparkinsonian medications other than levodopa, it is possible that individual medication regimens may influence dopaminergic neuronal status or the development of LID.
